biosimilars

Biogen to increase stake in biosimilar developer Samsung Bioepis
Biogen to increase stake in biosimilar developer Samsung Bioepis
Biopharma Dive
Biogen
biosimilars
Samsung Bioepis
Flag link:
Could Oral Biosimilars of Humira and Embrel Disrupt the Biologics Market?
Could Oral Biosimilars of Humira and Embrel Disrupt the Biologics Market?
Xtalks
biosimilars
Rani Therapeutics
Humira
Embrel
Flag link:
Overview of Pfizer's Biosimilar Program
Overview of Pfizer's Biosimilar Program
CP WIre
Pfizer
biosimilars
Flag link:
Overview of Pfizer's Biosimilar Program
Pfizer
biosimilars
Flag link:
FDA Fails to Approve Pfizer's Biosimilar of Roche's Herceptin
FDA Fails to Approve Pfizer's Biosimilar of Roche's Herceptin
CP Wire
Pfizer
FDA
Roche
Herceptin
biosimilars
Flag link:
FDA Fails to Approve Pfizer's Biosimilar of Roche's Herceptin
Pfizer
Herceptin
biosimilars
trastuzumab
Roche
Flag link:
Interview With Gottlieb: A Discussion on Biosimilars, Opioids and Transparency
Interview With Gottlieb: A Discussion on Biosimilars, Opioids and Transparency
RAPS.org
FDA
Scott Gottlieb
biosimilars
generics
opioids
transparency
Flag link:
Fujifilm Kyowa Kirin Biologics Partners with Mylan to Commercialize Biosimilar to Humira in Europe
Fujifilm Kyowa Kirin Biologics Partners with Mylan to Commercialize Biosimilar to Humira in Europe
CP Wire
Humira
Mylan
Fujifilm
AbbVie
biosimilars
FKB327
Flag link:
$21B or bust! AbbVie ensures its blockbuster US marathon on Humira will run into 2023
$21B or bust! AbbVie ensures its blockbuster US marathon on Humira will run into 2023
Endpoints
AbbVie
Humira
biosimilars
Flag link:
Novartis Likely Delayed In Launching Copycat Of Amgen Blockbuster
Novartis Likely Delayed In Launching Copycat Of Amgen Blockbuster
Investors Business Daily
Novartis
Amgen
Enbrel
biosimilars
Flag link:
In bid to lower prices, Gottlieb says FDA will take new action to speed approval of biosimilars
In bid to lower prices, Gottlieb says FDA will take new action to speed approval of biosimilars
Stat
FDA
Scott Gottlieb
biosimilars
drug approvals
Flag link:
Amgen and Allergan Hopeful that Herceptin Biosimilar Approval Will Be Around the Corner
Amgen and Allergan Hopeful that Herceptin Biosimilar Approval Will Be Around the Corner
Xtalks
Amgen
Allergan
Herceptin
biosimilars
ABP 980
CHMP
EMA
Roche
Flag link:
Gottlieb condemns ‘rigged payment scheme’ for biosimilar drugs
Gottlieb condemns ‘rigged payment scheme’ for biosimilar drugs
Stat
Gottlieb
biosimilars
FDA
drug pricing
Flag link:
Botox Biosimilar in Development by Mylan and Revance Therapeutics
Botox Biosimilar in Development by Mylan and Revance Therapeutics
Xtalks
Botox
Allergan
biosimilars
Mylan Labs
Revance Therapeutics
Flag link:
Mylan teams up with Revance on biosimilar for Botox
Mylan teams up with Revance on biosimilar for Botox
Reuters
Mylan Labs
ReVance
biosimilars
Botox
Flag link:
Momenta Pharmaceuticals Wraps Up a Bleak Year
Momenta Pharmaceuticals Wraps Up a Bleak Year
Motley Fool
Momenta Pharmaceuticals
earnings
biosimilars
generics
Flag link:
Express Scripts joins Walgreens Boots to lower biosimilar costs
Express Scripts joins Walgreens Boots to lower biosimilar costs
Biopharma Dive
Express Scripts
Walgreens Boots Alliance Development
ValoremRx
biosimilars
Flag link:
Remicade biosims from Pfizer, Merck unlikely to turn the tide in 2018: analyst
Remicade biosims from Pfizer, Merck unlikely to turn the tide in 2018: analyst
Fierce Pharma
Remicade
biosimilars
Pfizer
Merck
JNJ
Flag link:
Biosimilars Council Sides with Pfizer in Antitrust Dispute with J&J
Biosimilars Council Sides with Pfizer in Antitrust Dispute with J&J
JD Supra
biosimilars
Pfizer
JNJ
antitrust
Remicade
Inflectra
Flag link:
Pfizer’s latest copycat could put the squeeze on Roche — again
Pfizer’s latest copycat could put the squeeze on Roche — again
Endpoints
Pfizer
Roche
biosimilars
Rituxan
PF-05280586
Flag link:

Pages